• Users Online: 118
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 7  |  Issue : 1  |  Page : 15-19

Oral itraconazole and topical eberconazole therapy in the treatment of tinea cruris and corporis


1 LaMer Clinic, Mumbai, Maharashtra, India
2 Innovation Skin Clinic, Mumbai, Maharashtra, India

Correspondence Address:
Swagata Arvind Tambe
19/558, Udhyan Society, Nehru Nagar, Kurla East Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdd.ijdd_44_19

Rights and Permissions

Background: Dermatophytosis is a common fungal infection in India. In recent times, there has been a change in the course of the disease with an increase in the number of chronic, widespread, and recurrent cases. Aims and Objectives: The aim of this study is to (1) To study the clinical efficacy of itraconazole as a monotherapy in the treatment of tinea cruris and corporis and (2) To study the predictors of noncompliance to treatment in recurrence of infection. Methods: The current study was an unblinded prospective study conducted at a private clinic on 100 randomly selected patients, with a clinical and mycological diagnosis of tinea cruris and corporis. A detailed history was taken regarding the total duration of disease, duration of previous therapy, causes of noncompliance to previous treatmentand associated comorbidities after obtaining informed consent. The patients were put on a regime of oral itraconazole 100 mg twice daily and topical eberconazole twice daily for 12 weeks. Patients were followed up at 2, 6, 12 weeks, 6 months, and 1 year. Statistical analysis was performed using the SPSS software version 22. using appropriate statistical tests. Results: In our study, the mean age of the participants was 38 years, with the male: female ratio being 2.15:1. Only nine patients were treatment naïve, whereas 91 had received treatment previously. Most common factor responsible for discontinuation of therapy was partial relief which was mistaken as cure by the patient. Clinical cure rate at 2, 6, and 12 weeks was 38%, 68%, and 83%, respectively. Mycological cure rate at 2, 6, and 12 weeks was 56%, 81%, and 83%, respectively. Conclusion: itraconazole 100 mg twice daily is an effective and safe treatment for tinea cruris and corporis. Improving the patient's compliance and treatment adherence enhances the rate of clinical as well as mycological cure and avoids recurrences.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed807    
    Printed12    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal